Join today and be a part of the fastest growing B2B Network Join Now

Soliris 300mg

  • Origin: United Kingdom
  • Supply Type: in stock
  • Processing Time: 3 days
  • Min Order: 5

Quick Details

Batch No: PL2645/2 Expiry date: 03/2021

Supplier Info.

  • Company Name RCC Pharma AG
  • Membership:Free
  • Business Type: Distributor/Wholesaler
  • Employees Total 5
  • Annual Revenue

Soliris 30mg is a humanised monoclonal antibody that is a first-in-class terminal complement inhibitor and the first therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) , a rare, progressive, and sometimes life-threatening disease.

Its use and Indications Soliris is indicated for

    • The treatment of patients of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
    • The treatment of patients with atypical haemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy.

Treatment For treatment related information, please consult your treating sician.

How supplied: Soliris is supplied as 300 mg single-use vials each containing 30 ml of 10 mg/ml sterile, preservative-free eculizumab solution.

Storage and handling Soliris vials must be stored in the original carton until time of use under refrigerated conditions at 2-8°C and protected from light. DO NOT FREEZE, DO NOT SHAKE

How do we source the Drug? Super Specialities rma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.

Soliris 30mg is a humanised monoclonal antibody that is a first-in-class terminal complement inhibitor and the first therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) , a rare, progressive, and sometimes life-threatening disease.

Its use and Indications Soliris is indicated for

The treatment of patients of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical haemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy. Treatment For treatment related information, please consult your treating sician.

How supplied: Soliris is supplied as 300 mg single-use vials each containing 30 ml of 10 mg/ml sterile, preservative-free eculizumab solution.

Storage and handling Soliris vials must be stored in the original carton until time of use under refrigerated conditions at 2-8°C and protected from light. DO NOT FREEZE, DO NOT SHAKE

How do we source the Drug?RCC rma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.

Premium Services
Need Suppliers
Girl Right
Cross Popup
Arrow 2

I Am :

Signup today to claim your Discount. Get Started before it's too late!

Arrow 1
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok